Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplant.

Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, Perales MA, Papadopoulos E, Sauter C, Castro-Malaspina H, Boulad F, Curran KJ, Giralt S, Gyurkocza B, Hsu KC, Jakubowski A, Hanash AM, Kernan NA, Kobos R, Koehne G, Landau H, Ponce D, Spitzer B, Young JW, Behr G, Dunphy M, Haque S, Teruya-Feldstein J, Arcila M, Moung C, Hsu S, Hasan A, O'Reilly RJ.

J Clin Invest. 2019 Nov 5. pii: 121127. doi: 10.1172/JCI121127. [Epub ahead of print]

2.

Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.

Ito K, Lee J, Chrysanthou S, Zhao Y, Josephs K, Sato H, Teruya-Feldstein J, Zheng D, Dawlaty MM, Ito K.

Cell Rep. 2019 Sep 3;28(10):2480-2490.e4. doi: 10.1016/j.celrep.2019.07.094.

3.

Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms.

Shank K, Dunbar A, Koppikar P, Kleppe M, Teruya-Feldstein J, Csete I, Bhagwat N, Keller M, Kilpivaara O, Michor F, Levine RL, de Vargas Roditi L.

Haematologica. 2019 Aug 14. pii: haematol.2018.203729. doi: 10.3324/haematol.2018.203729. [Epub ahead of print]

4.

Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma.

Hao Y, Khaykin D, Machado L, van den Akker T, Houldsworth J, Barlogie B, Hussein S, El Jamal SM, Petersen B, Teruya-Feldstein J.

Mod Pathol. 2019 Aug 2. doi: 10.1038/s41379-019-0333-6. [Epub ahead of print]

PMID:
31375765
5.

Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway.

Lee YR, Chen M, Lee JD, Zhang J, Lin SY, Fu TM, Chen H, Ishikawa T, Chiang SY, Katon J, Zhang Y, Shulga YV, Bester AC, Fung J, Monteleone E, Wan L, Shen C, Hsu CH, Papa A, Clohessy JG, Teruya-Feldstein J, Jain S, Wu H, Matesic L, Chen RH, Wei W, Pandolfi PP.

Science. 2019 May 17;364(6441). pii: eaau0159. doi: 10.1126/science.aau0159.

PMID:
31097636
6.

Immune dysregulation: EBV+ DLBCL and HLH in a patient with T-LGL.

Zhan Y, Teruya-Feldstein J.

Blood. 2019 Apr 11;133(15):1695. doi: 10.1182/blood-2019-01-899484. No abstract available.

PMID:
30975643
7.

MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.

El Jamal SM, Grada Z, El Dinali MH, Zhou H, Hassan SY, Saad AG, Gibson B, Zhou X, Abulsayen HA, Khadra HS, Friedman J, Shalaby H, Kadi A, Megahed M, Emberesh M, Teruya-Feldstein J, Firpo-Betancourt A, Haikel Y, Fraig M, Hassan M.

Lab Invest. 2019 Apr;99(4):539-550. doi: 10.1038/s41374-018-0152-2. Epub 2018 Nov 16.

PMID:
30446717
8.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.

J Clin Invest. 2018 Oct 1;128(10):4743. doi: 10.1172/JCI124920. Epub 2018 Sep 17. No abstract available.

9.

nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin.

Saad AG, Grada Z, Bishop B, Abulsayen H, Hassan M, Firpo-Betancourt A, Teruya-Feldstein J, Fraig M, El Jamal SM.

Appl Immunohistochem Mol Morphol. 2019 Oct;27(9):644-648. doi: 10.1097/PAI.0000000000000696.

PMID:
30179888
10.

Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab.

Matsuki E, Bohn OL, El Jamal S, Pichardo JD, Zelenetz AD, Younes A, Teruya-Feldstein J.

Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):572-580. doi: 10.1097/PAI.0000000000000645.

PMID:
30106758
11.

Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study.

Merzianu M, Groman A, Hutson A, Cotta C, Brynes RK, Orazi A, Reddy V, Teruya-Feldstein J, Amre R, Balasubramanian M, Brandao G, Cherian S, Courville E, Czuchlewski D, Fan G, Grier D, Hoehn D, Inamdar KV, Juskevicius R, Kaur P, Lazarchick J, Lewis MR, Miles RR, Myers JB, Nasr MR, Qureishi HN, Olteanu H, Robu VG, Salaru G, Vajpayee N, Vos J, Zhang L, Zhang S, Aye L, Brega E, Coad JE, Grantham J, Ivelja S, McKenna R, Sultan K, Wilding G, Hutchison R, Peterson L, Cheney RT.

Am J Clin Pathol. 2018 Oct 1;150(5):393-405. doi: 10.1093/ajcp/aqy066.

12.

A Rare Cause of Pancytopenia in an Exclusively Breastfed Infant.

Bobb-Semple AA, Lau CS, Teruya-Feldstein J, Wistinghausen B.

J Pediatr Hematol Oncol. 2019 Jul;41(5):e322-e324. doi: 10.1097/MPH.0000000000001246.

PMID:
30028821
13.

Adult-Onset Still's Disease and Macrophage-Activating Syndrome Progressing to Lymphoma: A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery.

Mehta B, Kasturi S, Teruya-Feldstein J, Horwitz S, Bass AR, Erkan D.

HSS J. 2018 Jul;14(2):214-221. doi: 10.1007/s11420-018-9606-8. Epub 2018 Mar 26. No abstract available.

14.

LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone.

Jutzi JS, Kleppe M, Dias J, Staehle HF, Shank K, Teruya-Feldstein J, Gambheer SMM, Dierks C, Rienhoff HY Jr, Levine RL, Pahl HL.

Hemasphere. 2018 Jun 8;2(3):e54. doi: 10.1097/HS9.0000000000000054. eCollection 2018 Jun.

15.

Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs.

Chang CJ, Kotini AG, Olszewska M, Georgomanoli M, Teruya-Feldstein J, Sperber H, Sanchez R, DeVita R, Martins TJ, Abdel-Wahab O, Bradley RK, Papapetrou EP.

Stem Cell Reports. 2018 May 8;10(5):1610-1624. doi: 10.1016/j.stemcr.2018.03.020. Epub 2018 Apr 19.

16.

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.

Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL.

Cancer Cell. 2018 Apr 9;33(4):785-787. doi: 10.1016/j.ccell.2018.03.024. No abstract available.

17.

Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis.

Kleppe M, Spitzer MH, Li S, Hill CE, Dong L, Papalexi E, De Groote S, Bowman RL, Keller M, Koppikar P, Rapaport FT, Teruya-Feldstein J, Gandara J, Mason CE, Nolan GP, Levine RL.

Cell Stem Cell. 2018 Feb 1;22(2):277. doi: 10.1016/j.stem.2017.12.018. No abstract available.

18.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, Shank K, Rapaport FT, Patel MA, Papalexi E, Shih AH, Chiu A, Freinkman E, Akbay EA, Steadman M, Nagaraja R, Yen K, Teruya-Feldstein J, Wong KK, Rampal R, Vander Heiden MG, Thompson CB, Levine RL.

J Clin Invest. 2018 Feb 1;128(2):789-804. doi: 10.1172/JCI94516. Epub 2018 Jan 22. Erratum in: J Clin Invest. 2018 Oct 1;128(10):4743.

19.

An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez-Billalabeitia E, Liu XS, Lee YR, Fung J, Katon JM, Menon AV, Webster KA, Ng C, Palumbieri MD, Diolombi MS, Breitkopf SB, Teruya-Feldstein J, Signoretti S, Bronson RT, Asara JM, Castillo-Martin M, Cordon-Cardo C, Pandolfi PP.

Nat Genet. 2018 Feb;50(2):206-218. doi: 10.1038/s41588-017-0027-2. Epub 2018 Jan 15.

20.

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.

Kleppe M, Koche R, Zou L, van Galen P, Hill CE, Dong L, De Groote S, Papalexi E, Hanasoge Somasundara AV, Cordner K, Keller M, Farnoud N, Medina J, McGovern E, Reyes J, Roberts J, Witkin M, Rapaport F, Teruya-Feldstein J, Qi J, Rampal R, Bernstein BE, Bradner JE, Levine RL.

Cancer Cell. 2018 Jan 8;33(1):29-43.e7. doi: 10.1016/j.ccell.2017.11.009. Epub 2017 Dec 14. Erratum in: Cancer Cell. 2018 Apr 9;33(4):785-787.

21.

Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis.

Kleppe M, Spitzer MH, Li S, Hill CE, Dong L, Papalexi E, De Groote S, Bowman RL, Keller M, Koppikar P, Rapaport FT, Teruya-Feldstein J, Gandara J, Mason CE, Nolan GP, Levine RL.

Cell Stem Cell. 2017 Oct 5;21(4):489-501.e7. doi: 10.1016/j.stem.2017.08.011. Epub 2017 Sep 28. Erratum in: Cell Stem Cell. 2018 Feb 1;22(2):277.

22.

Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.

Kotini AG, Chang CJ, Chow A, Yuan H, Ho TC, Wang T, Vora S, Solovyov A, Husser C, Olszewska M, Teruya-Feldstein J, Perumal D, Klimek VM, Spyridonidis A, Rampal RK, Silverman L, Reddy EP, Papaemmanuil E, Parekh S, Greenbaum BD, Leslie CS, Kharas MG, Papapetrou EP.

Cell Stem Cell. 2017 Mar 2;20(3):315-328.e7. doi: 10.1016/j.stem.2017.01.009. Epub 2017 Feb 16.

23.

Radiation for MALT of the Submandibular Gland.

Chadha J, Teng MS, Teruya-Feldstein J, Bakst RL.

Case Rep Hematol. 2017;2017:8397621. doi: 10.1155/2017/8397621. Epub 2017 Jan 9.

24.

#InSituPathologists: how the #USCAP2015 meeting went viral on Twitter and founded the social media movement for the United States and Canadian Academy of Pathology.

Cohen D, Allen TC, Balci S, Cagle PT, Teruya-Feldstein J, Fine SW, Gondim DD, Hunt JL, Jacob J, Jewett K, Jiang X', Kaplan KJ, Kulac I, Meunier R, Riddle ND, Rush PS, Stall J, Stuart LN, Terrano D, Uthman E, Wasco MJ, Williamson SR, Wu RI, Gardner JM.

Mod Pathol. 2017 Feb;30(2):160-168. doi: 10.1038/modpathol.2016.223. Epub 2017 Jan 13.

25.

Self-renewal of a purified Tie2+ hematopoietic stem cell population relies on mitochondrial clearance.

Ito K, Turcotte R, Cui J, Zimmerman SE, Pinho S, Mizoguchi T, Arai F, Runnels JM, Alt C, Teruya-Feldstein J, Mar JC, Singh R, Suda T, Lin CP, Frenette PS, Ito K.

Science. 2016 Dec 2;354(6316):1156-1160. Epub 2016 Oct 13.

26.

Metastatic Follicular Lymphoma Identified on Surveillance Colonoscopy.

Nulsen B, Ungaro RC, Teruya-Feldstein J, Waye JD.

Am J Gastroenterol. 2016 Oct;111(10):1380. doi: 10.1038/ajg.2016.245. No abstract available.

PMID:
27694862
27.

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.

Boice M, Salloum D, Mourcin F, Sanghvi V, Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G, Tam W, Teruya-Feldstein J, de Stanchina E, Chan WC, Malek SN, Ennishi D, Brentjens RJ, Gascoyne RD, Cogné M, Tarte K, Wendel HG.

Cell. 2016 Oct 6;167(2):405-418.e13. doi: 10.1016/j.cell.2016.08.032. Epub 2016 Sep 29.

28.

PIAS1 Promotes Lymphomagenesis through MYC Upregulation.

Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S, Scaglioni PP.

Cell Rep. 2016 Jun 7;15(10):2266-2278. doi: 10.1016/j.celrep.2016.05.015. Epub 2016 May 26.

29.

Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells.

Guryanova OA, Lieu YK, Garrett-Bakelman FE, Spitzer B, Glass JL, Shank K, Martinez AB, Rivera SA, Durham BH, Rapaport F, Keller MD, Pandey S, Bastian L, Tovbin D, Weinstein AR, Teruya-Feldstein J, Abdel-Wahab O, Santini V, Mason CE, Melnick AM, Mukherjee S, Levine RL.

Leukemia. 2016 May;30(5):1133-42. doi: 10.1038/leu.2015.358. Epub 2015 Dec 29.

30.

Elucidation and Pharmacological Targeting of Novel Molecular Drivers of Follicular Lymphoma Progression.

Bisikirska B, Bansal M, Shen Y, Teruya-Feldstein J, Chaganti R, Califano A.

Cancer Res. 2016 Feb 1;76(3):664-74. doi: 10.1158/0008-5472.CAN-15-0828. Epub 2015 Nov 20.

31.

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.

Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Sanchez Martin M, Dong L, Tallman MS, Paietta E, Wang K, He J, Lipson D, Stephens P, Miller V, Rowe JM, Teruya-Feldstein J, Mullighan CG, Ferrando AA, Krivtsov A, Armstrong S, Leung L, Ochiana SO, Chiosis G, Levine RL, Kleppe M.

Blood. 2015 Nov 26;126(22):2479-83. doi: 10.1182/blood-2015-03-635821. Epub 2015 Oct 6.

32.

Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center.

Watts JM, Kishtagari A, Hsu M, Lacouture ME, Postow MA, Park JH, Stein EM, Teruya-Feldstein J, Abdel-Wahab O, Devlin SM, Tallman MS.

Br J Haematol. 2015 Oct;171(1):84-90. doi: 10.1111/bjh.13528. Epub 2015 Jun 26.

33.

FoxO1-dependent induction of acute myeloid leukemia by osteoblasts in mice.

Kode A, Mosialou I, Manavalan SJ, Rathinam CV, Friedman RA, Teruya-Feldstein J, Bhagat G, Berman E, Kousteni S.

Leukemia. 2016 Jan;30(1):1-13. doi: 10.1038/leu.2015.161. Epub 2015 Jun 25.

34.

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Teruya-Feldstein J, Murakami M, Radimerski T, Michor F, Fan R, Levine RL.

Cancer Discov. 2015 Mar;5(3):316-31. doi: 10.1158/2159-8290.CD-14-0736. Epub 2015 Jan 8.

35.

Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology.

Ishikawa Y, Maeda M, Pasham M, Aguet F, Tacheva-Grigorova SK, Masuda T, Yi H, Lee SU, Xu J, Teruya-Feldstein J, Ericsson M, Mullally A, Heuser J, Kirchhausen T, Maeda T.

Haematologica. 2015 Apr;100(4):439-51. doi: 10.3324/haematol.2014.119537. Epub 2014 Dec 31.

36.

Clinical features and outcome of primary pancreatic lymphoma.

Sadot E, Yahalom J, Do RK, Teruya-Feldstein J, Allen PJ, Gönen M, D'Angelica MI, Kingham TP, Jarnagin WR, DeMatteo RP.

Ann Surg Oncol. 2015 Apr;22(4):1176-84. doi: 10.1245/s10434-014-4176-6. Epub 2014 Oct 24.

37.

Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis.

Schatz JH, Horwitz SM, Teruya-Feldstein J, Lunning MA, Viale A, Huberman K, Socci ND, Lailler N, Heguy A, Dolgalev I, Migliacci JC, Pirun M, Palomba ML, Weinstock DM, Wendel HG.

Leukemia. 2015 Jan;29(1):237-41. doi: 10.1038/leu.2014.261. Epub 2014 Sep 3. No abstract available.

38.

A cell engineering strategy to enhance the safety of stem cell therapies.

Oricchio E, Papapetrou EP, Lafaille F, Ganat YM, Kriks S, Ortega-Molina A, Mark WH, Teruya-Feldstein J, Huse JT, Reuter V, Sadelain M, Studer L, Wendel HG.

Cell Rep. 2014 Sep 25;8(6):1677-1685. doi: 10.1016/j.celrep.2014.08.039. Epub 2014 Sep 18.

39.

The diagnosis and treatment of dyskeratosis congenita: a review.

Fernández García MS, Teruya-Feldstein J.

J Blood Med. 2014 Aug 21;5:157-67. doi: 10.2147/JBM.S47437. eCollection 2014. Review.

40.

Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts.

Krevvata M, Silva BC, Manavalan JS, Galan-Diez M, Kode A, Matthews BG, Park D, Zhang CA, Galili N, Nickolas TL, Dempster DW, Dougall W, Teruya-Feldstein J, Economides AN, Kalajzic I, Raza A, Berman E, Mukherjee S, Bhagat G, Kousteni S.

Blood. 2014 Oct 30;124(18):2834-46. doi: 10.1182/blood-2013-07-517219. Epub 2014 Aug 18.

41.

RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.

Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van der Meulen J, Schatz JH, Rodrigo CM, Zhao C, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA Jr, Pelletier J, Rätsch G, Wendel HG.

Nature. 2014 Sep 4;513(7516):65-70. doi: 10.1038/nature13485. Epub 2014 Jul 27.

42.

Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.

Oricchio E, Ciriello G, Jiang M, Boice MH, Schatz JH, Heguy A, Viale A, de Stanchina E, Teruya-Feldstein J, Bouska A, McKeithan T, Sander C, Tam W, Seshan VE, Chan WC, Chaganti RS, Wendel HG.

J Exp Med. 2014 Jun 30;211(7):1379-91. doi: 10.1084/jem.20132120. Epub 2014 Jun 9.

43.

Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.

Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, Hu W, Beguelin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Huberman K, Bouvier N, Berger MF, Melnick AM, Rosen N, Tallman MS, Park CY, Abdel-Wahab O.

Sci Transl Med. 2014 May 28;6(238):238ra71. doi: 10.1126/scitranslmed.3008004.

44.

PTEN action in leukaemia dictated by the tissue microenvironment.

Miething C, Scuoppo C, Bosbach B, Appelmann I, Nakitandwe J, Ma J, Wu G, Lintault L, Auer M, Premsrirut PK, Teruya-Feldstein J, Hicks J, Benveniste H, Speicher MR, Downing JR, Lowe SW.

Nature. 2014 Jun 19;510(7505):402-6. doi: 10.1038/nature13239. Epub 2014 May 4.

45.

miR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion.

Chen D, Sun Y, Yuan Y, Han Z, Zhang P, Zhang J, You MJ, Teruya-Feldstein J, Wang M, Gupta S, Hung MC, Liang H, Ma L.

PLoS Genet. 2014 Feb 27;10(2):e1004177. doi: 10.1371/journal.pgen.1004177. eCollection 2014 Feb.

46.

BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.

Bohn OL, Hsu K, Hyman DM, Pignataro DS, Giralt S, Teruya-Feldstein J.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):e65-8. doi: 10.1016/j.clml.2013.12.003. Epub 2013 Dec 17. No abstract available.

PMID:
24445188
47.

Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts.

Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R, Brum A, Park D, Galili N, Mukherjee S, Teruya-Feldstein J, Raza A, Rabadan R, Berman E, Kousteni S.

Nature. 2014 Feb 13;506(7487):240-4. doi: 10.1038/nature12883. Epub 2014 Jan 15.

48.

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, Dorfman D, Stevenson K, Rodig SJ, Piccaluga PP, Jacobsen E, Pileri SA, Harris NL, Ferrero S, Inghirami G, Horwitz SM, Weinstock DM.

Blood. 2014 Feb 27;123(9):1293-6. doi: 10.1182/blood-2013-10-531509. Epub 2013 Dec 17.

49.

Utility of LRF/Pokemon and NOTCH1 protein expression in the distinction between nodular lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma.

Bohn O, Maeda T, Filatov A, Lunardi A, Pandolfi PP, Teruya-Feldstein J.

Int J Surg Pathol. 2014 Feb;22(1):6-11. doi: 10.1177/1066896913513833. Epub 2013 Dec 10.

50.

Detection of an NRAS mutation in Erdheim-Chester disease.

Diamond EL, Abdel-Wahab O, Pentsova E, Borsu L, Chiu A, Teruya-Feldstein J, Hyman DM, Rosenblum M.

Blood. 2013 Aug 8;122(6):1089-91. doi: 10.1182/blood-2013-02-482984. No abstract available.

PMID:
23929840

Supplemental Content

Loading ...
Support Center